^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    bevacizumab biosimilar

    Associations

    News

    Trials
    Company:
    Axis Biotec, Fraunhofer-Institute of Toxicology and Experimental Medicine, PlantForm
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. (PubMed, Cells)
    The study showed that Sorafenib regulates a specific miRNA signature in which miR-200c-3p, miR-222-5p, and miR-512-3p bear prognostic value and contribute to treatment response.
    Journal • PD(L)-1 Biomarker
    |
    MIR200C (MicroRNA 200c) • MIR193B (MicroRNA 193b) • MIR27A (MicroRNA 27a) • MIR375 (MicroRNA 375) • MIR122 (MicroRNA 122) • MIR194 (MicroRNA 194) • MIR222 (MicroRNA 222)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • bevacizumab biosimilar